MEDI-563, a Humanized Anti-IL-5Ra Antibody with Enhanced Effector Function, Induces Reversible Blood Eosinopenia in Mild Asthmatics
Jennifer L. Reed(Cincinnati Children's Hospital Medical Center), Barbara White, Anthony J. Coyle(Immune Regulation (United Kingdom)), William W. Busse(University of Wisconsin–Madison), Francisco James León Trujillo, Jonas S. Erjefält(Lund University), Alison A. Humbles(Institute of Neuroimmunology of the Slovak Academy of Sciences), Masami Koike(Princeton University), Rohit Katial(National Jewish Health), Peter A. Kiener(Institute of Neuroimmunology of the Slovak Academy of Sciences), R. Kolbeck, A A Kozhich, George L. Spitalny(Princeton University), Néstor A. Molfino(Amgen (United States))
Cited by 10
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
|New England Journal of Medicine|2011|870
Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma
|Journal of Allergy and Clinical Immunology|2010|746